@2024 - All Right Reserved.
BRCA- and tumor suppressor gene mutations are associated with worse overall survival among patients receiving lutetium-177 PSMA radioligand therapy for mCRPC. Lutetium-177-PMSA radioligand therapy (Lu ...
Lu-177 dotatate is a molecular therapy. It is a type of peptide receptor radionuclide therapy (PRRT) used mainly for neuroendocrine tumors (NETs). PRRT combines a compound called a peptide with a ...
Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...
Business Daily Africa on MSN
The Sh1 million-a-dose new prostate cancer treatment
Men with aggressive prostate cancer, often left with few options after chemotherapy fails, now have access to a new treatment that uses a radioactive substance.The new treatment, Lutetium-177 PSMA ...
or on the link below. ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid ...
Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with radioligand intensification despite early on-treatment score fluctuations. FACT-P ...
RFH Healthcare Managing Director Maxwel Okoth addresses a past press breifing. [File, Standard] RFH Healthcare has announced a medical milestone with the successful administration of Lutetium therapy ...
Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 Ra) ...
TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations. This is an ASCO Meeting Abstract from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results